SCHEMBL9883141

SCHEMBL9883141

CCc1ccc2c(O)nc(Cl)cc2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.41
CYP1A2 P05177 1/20 0.40
CYP2A6 P11509 1/20 0.40
SMN1; SMN2 Q16637 4/20 0.38
ELANE P08246 1/20 0.36
GAA P10253 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
KDM4E B2RXH2 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
HIF1A Q16665 1/20 0.36
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
NOS2 P35228 1/20 0.34
KIF11 P52732 1/20 0.34
AKR1C3 P42330 1/20 0.34
AKR1C2 P52895 1/20 0.34
DAO P14920 1/20 0.34
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9883152 0.81 TRPA1 (0.42) TRPA1CYP1A2CYP2A6SMN1; SMN2ELANE
SCHEMBL17232439 0.79 SMN1; SMN2 (0.44) CYP1A2CYP2A6SMN1; SMN2GAAKDM4E
SCHEMBL15047875 0.77 CYP1A2 (0.39) TRPA1CYP1A2CYP2A6GAANPSR1
SCHEMBL8352162 0.74 NOS3 (0.47) TRPA1CYP1A2CYP2A6SMN1; SMN2GAA
SCHEMBL9880943 0.72 ALDH1A1 (0.41) SMN1; SMN2GAACYP2C19KIF11AKR1C2
SCHEMBL12064451 0.72 TRPA1 (0.41) TRPA1CYP1A2CYP2A6SMN1; SMN2ELANE
SCHEMBL19256970 0.72 CNR2 (0.38)
SCHEMBL3083764 0.70 TRPM4 (0.45) CYP1A2CYP2A6KDM4ECYP2C19HIF1A
SCHEMBL26027606 0.69 TRPA1 (0.50) TRPA1CYP1A2CYP2A6GAAKDM4E
SCHEMBL17221498 0.68 RECQL (0.44) KDM4ECYP3A4CYP2C19HIF1AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8394826-B2 Dual mechanism inhibitors for the treatment of disease AERIE PHARMACEUTICALS, INC. (US) 2013-03-12 US disclosed
US-20120135984-A1 DUAL-ACTION INHBITORS AND METHODS OF USING SAME AERIE PHARMACEUTICALS, INC. 2012-05-31 US disclosed
US-20100280011-A1 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE ALCON INC. (CH) 2010-11-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120135984-A1 DUAL-ACTION INHBITORS AND METHODS OF USING SAME SLC6A2, ROCK2, SLC6A4 TRPA1 4080/4885CYP1A2 1088/4885CYP2A6 2518/4885
US-20100280011-A1 DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE RHOA, SLC6A2, ROCK2 TRPA1 3206/4885CYP1A2 1339/4885CYP2A6 2488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.